Eli Lilly & Co. has revised its revenue guidance for the fourth quarter of 2024 downwards to $13.5 billion, $400 million below the previously anticipated range of $13.9 billion to $14.5 billion and analyst expectations of $14 billion. The company attributed the shortfall to lower-than-expected sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro, with projected sales of $1.9 billion and $3.5 billion respectively, both below consensus estimates. Despite the fourth-quarter miss, Eli Lilly reported a full-year 2024 revenue of approximately $45 billion, marking a 32% increase from 2023. For 2025, the company forecasts revenue to be between $58 billion and $61 billion, surpassing the consensus estimate of $58.48 billion. The stock experienced a significant decline of about 8% following the announcement, reflecting investor concerns over the slower-than-expected growth in the GLP-1 drug market.